| Ytd | 63.61% | |
| 1y | -29.61% |
| Open | 21.92 | Prev Close | 21.89 | Low | 21.23 | High | 22.00 | Mkt Cap | 1.27B |
| Vol | 3.73M | Avg Vol | 1.12M | EPS | 180.58 | P/E | 0.12 | Forward P/E | -5.61 |
| Beta | 1.72 | Short Ratio | 10.11 | Inst. Own | 86.45% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 21.79 | 200-d Avg | 16.23 | 1yr Est | 39.00 |
VOR News
Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a
Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Topline results from UPSTREAM MG's 24-week primary endpoint remain on track for first half of 2027 G
BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology com
Bank of America Corp DE increased its position in Vor Biopharma Inc. (NASDAQ: VOR) by 28,408.1% duri
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology com
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the pr
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.80) per share which missed the analyst c
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(1.16) per share which missed the analyst c
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis p
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp
Vor Biopharma (VOR) has transformed into a late-stage autoimmune drug developer, focusing on telitac
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology comp
Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery for
First regulatory approval for Sjögren's disease (SjD) First and only approved therapy for SjD in Chi
First and only approved BAFF/APRIL-targeting therapy for IgA nephropathy (IgAN) Approval based on p
BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnolo
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology compa
Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks w
Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis p
The consensus price target hints at a 124.6% upside potential for Vor Biopharma (VOR). While empiric
Top Wall Street analysts changed their outlook on these top names. See analyst rating changes and up
U.S. stocks lower, Nasdaq falls 1%. Oxford Industries up 11.2% on strong earnings, raised dividend.
XCUR: 176% | Exicure shares are trading higher after the company announced results from its complete
